{
    "name": "caplacizumab",
    "comment": "Rx",
    "other_names": [
        "Cablivi",
        "caplacizumab-yhdp"
    ],
    "classes": [
        "Monoclonal Antibodies",
        "Antiplatelet Agents",
        "Hematologic"
    ],
    "source": "https://reference.medscape.com/drug/cablivi-caplacizumab-1000293",
    "pregnancy": {
        "common": [
            "Data are not available regarding use in pregnant women for risk of birth defects and miscarriage; however, there are potential risks of hemorrhage in the mother and fetus associated with caplacizumab use"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "No evidence of adverse developmental outcomes with IM administration during organogenesis in guinea pigs at exposures ~30x the human AUC at the recommended SC 11-mg dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data are available regrading presence in human milk, effects on breastfed infants, or on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Documented hypersensitivity, including urticaria"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Bleeding",
                    "description": [
                        "Increases bleeding risk; severe bleeding (epistaxis, gingival bleeding, upper GI hemorrhage, metrorrhagia) observed in clinical trials",
                        "Cases of life-threatening and fatal bleeding were reported",
                        "Risk of bleeding is increased in patients with underlying coagulopathies (eg, hemophilia, other coagulation factor deficiencies)",
                        "Avoid coadministration with antiplatelet agents or anticoagulants; interrupt use if clinically significant bleeding occurs; if restarted after bleed resolves, monitor closely for signs of bleeding",
                        "If needed, von Willebrand factor concentrate may be administered to rapidly correct hemostasis or if emergent surgery needed",
                        "Withhold for 7 days before surgery or other invasive interventions"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abciximab",
            "description": {
                "common": "caplacizumab, abciximab.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alteplase",
            "description": {
                "common": "caplacizumab, alteplase.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anagrelide",
            "description": {
                "common": "caplacizumab, anagrelide.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "caplacizumab, antithrombin alfa.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "caplacizumab, antithrombin III.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apixaban",
            "description": {
                "common": "caplacizumab, apixaban.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "argatroban",
            "description": {
                "common": "caplacizumab, argatroban.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aspirin",
            "description": {
                "common": "caplacizumab, aspirin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "caplacizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betrixaban",
            "description": {
                "common": "caplacizumab, betrixaban.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "caplacizumab, bivalirudin.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "caplacizumab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cangrelor",
            "description": {
                "common": "caplacizumab, cangrelor.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cilostazol",
            "description": {
                "common": "caplacizumab, cilostazol.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "caplacizumab, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "caplacizumab, clopidogrel.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dabigatran",
            "description": {
                "common": "caplacizumab, dabigatran.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dalteparin",
            "description": {
                "common": "caplacizumab, dalteparin.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dipyridamole",
            "description": {
                "common": "caplacizumab, dipyridamole.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "edoxaban",
            "description": {
                "common": "caplacizumab, edoxaban.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "caplacizumab, enoxaparin.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eptifibatide",
            "description": {
                "common": "caplacizumab, eptifibatide.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "caplacizumab, fondaparinux.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "heparin",
            "description": {
                "common": "caplacizumab, heparin.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "caplacizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "caplacizumab and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "caplacizumab, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentosan polysulfate sodium",
            "description": {
                "common": "caplacizumab, pentosan polysulfate sodium.\nEither increases effects of the other by anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prasugrel",
            "description": {
                "common": "caplacizumab, prasugrel.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "reteplase",
            "description": {
                "common": "caplacizumab, reteplase.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "caplacizumab, rivaroxaban.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tenecteplase",
            "description": {
                "common": "caplacizumab, tenecteplase.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "caplacizumab, ticagrelor.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tirofiban",
            "description": {
                "common": "caplacizumab, tirofiban.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "caplacizumab, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "caplacizumab, vorapaxar.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "caplacizumab, zanubrutinib.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of caplacizumab by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and caplacizumab both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Epistaxis",
            "percent": "29"
        },
        {
            "name": "Headache",
            "percent": "21"
        },
        {
            "name": "Gingival bleeding",
            "percent": "16"
        },
        {
            "name": "Fatigue",
            "percent": "15"
        },
        {
            "name": "Urticaria",
            "percent": "14"
        },
        {
            "name": "Pyrexia",
            "percent": "13"
        },
        {
            "name": "Paresthesia",
            "percent": "12"
        },
        {
            "name": "Dyspnea",
            "percent": "9"
        },
        {
            "name": "Back pain",
            "percent": "7"
        },
        {
            "name": "Myalgia",
            "percent": "6"
        },
        {
            "name": "Urinary tract infection",
            "percent": "6"
        },
        {
            "name": "Vaginal hemorrhage",
            "percent": "5"
        },
        {
            "name": "Rectal hemorrhage",
            "percent": "4"
        },
        {
            "name": "Hematuria",
            "percent": "4"
        },
        {
            "name": "Menorrhagia",
            "percent": "4"
        },
        {
            "name": "Abdominal wall hematoma",
            "percent": "3"
        },
        {
            "name": "Injection site erythema",
            "percent": null
        }
    ]
}